Advertisement
Advertisement

AGIO

AGIO logo

Agios Pharmaceuticals, Inc.

35.14
USD
Sponsored
+0.22
+0.63%
Apr 17, 16:00 UTC -4
Closed
exchange

After-Market

35.13

-0.01
-0.01%

AGIO Earnings Reports

Positive Surprise Ratio

AGIO beat 27 of 40 last estimates.

68%

Next Report

Date of Next Report
Apr 29, 2026
Estimate for Q1 26 (Revenue/ EPS)
$14.26M
/
-$1.84
Implied change from Q4 25 (Revenue/ EPS)
-28.68%
/
-1.08%
Implied change from Q1 25 (Revenue/ EPS)
+63.47%
/
+18.71%

Agios Pharmaceuticals, Inc. earnings per share and revenue

On Feb 12, 2026, AGIO reported earnings of -1.86 USD per share (EPS) for Q4 25, beating the estimate of -1.98 USD, resulting in a 6.31% surprise. Revenue reached 20.00 million, compared to an expected 12.25 million, with a 63.21% difference. The market reacted with a +1.30% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 7 analysts forecast an EPS of -1.84 USD, with revenue projected to reach 14.26 million USD, implying an decrease of -1.08% EPS, and decrease of -28.68% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Apr 08, 2026 For Q1 26
Estimate
-$0.76
Actual
-$0.79
Surprise
-2.68%
logo
NovaBridge Biosciences - ADR
Report Date
Apr 07, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.28
Surprise
-421.58%
logo
KALA BIO, Inc. Common Stock
Report Date
Apr 15, 2026 For Q4 25
Estimate
-$1.46
Actual
-$0.67
Surprise
+54.38%
logo
Scilex Holding Company Common Stock
Report Date
Apr 10, 2026 For Q4 25
Estimate
-$0.47
Actual
-$2.21
Surprise
-360.99%
logo
Lexaria Bioscience Corp. Common Stock
Report Date
Apr 13, 2026 For Q2 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+38.08%
logo
Quince Therapeutics, Inc. Common Stock
Report Date
Apr 10, 2026 For Q4 25
Estimate
-$1.92
Actual
-$7.10
Surprise
-268.68%
logo
GeoVax Labs, Inc. New
Report Date
Apr 15, 2026 For Q4 25
Estimate
-$6.29
Actual
$0.00
Surprise
+99.92%
FAQ
For Q4 2025, Agios Pharmaceuticals, Inc. reported EPS of -$1.86, beating estimates by 6.31%, and revenue of $20.00M, 63.21% above expectations.
The stock price moved up 1.3%, changed from $27.71 before the earnings release to $28.07 the day after.
The next earning report is scheduled for Apr 29, 2026.
Based on 7 analysts, Agios Pharmaceuticals, Inc. is expected to report EPS of -$1.84 and revenue of $14.26M for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement